Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Current Assets data on record, last reported at $1.2 billion in Q2 2025.

  • For Q2 2025, Current Assets rose 39.15% year-over-year to $1.2 billion; the TTM value through Jun 2025 reached $1.2 billion, up 39.15%, while the annual FY2024 figure was $1.4 billion, 139.55% up from the prior year.
  • Current Assets reached $1.2 billion in Q2 2025 per CRNX's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.4 billion in Q4 2024 and bottomed at $157.8 million in Q1 2021.
  • Average Current Assets over 5 years is $593.3 million, with a median of $397.3 million recorded in 2022.
  • Peak YoY movement for Current Assets: tumbled 31.58% in 2023, then skyrocketed 207.14% in 2024.
  • A 5-year view of Current Assets shows it stood at $344.7 million in 2021, then grew by 0.13% to $345.2 million in 2022, then soared by 66.33% to $574.2 million in 2023, then soared by 139.55% to $1.4 billion in 2024, then fell by 11.5% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $1.2 billion in Q2 2025, $1.3 billion in Q1 2025, and $1.4 billion in Q4 2024.